Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 12 June 2018

Indication(s)

PROCYSBI is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Fabry Disease

Fabry Disease

Explore the pathophysiology and treatment options for Fabry disease, a deficiency of the lysosomal enzyme alpha-galactosidase A

Hunter Syndrome

Hunter Syndrome

Hunter syndrome (MPS II) has symptoms which overlap with many common childhood complaints – do you know what to look for?

Hyperammonaemia

Hyperammonaemia

Hyperammonaemia can result in serious neurological damage or death. Could you recognise the signs and symptoms?

+ 2 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/002465
Orphan designation Yes
Date First Approved 06-09-2013
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Chiesi Farmaceutici S.p.A